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Abstract 1 
 2 
Background: Grading scales yield objective measure of the severity of aneurysmal subarachnoid hemorrhage and 3 
serve as to guide to treatment decisions and for prognostication. The purpose of this cohort study was to 4 
determine what factors govern a patient’s disease-specific scores in a representative Central European cohort. 5 
 6 
Methods: The Swiss Study of Subarachnoid Hemorrhage includes anonymized data from all tertiary referral 7 
centers serving subarachnoid hemorrhage patients in Switzerland. The 2009-2014 dataset was used to evaluate 8 
the impact of patient- and aneurysm-characteristics on the patients’ status at admission using descriptive and 9 
multivariate regression analysis. The primary/co-primary endpoints were the GCS and the WFNS grade. The 10 
secondary endpoints were the Fisher grade, the presence of a thick intraventricular clot, the presence of a new 11 
neurological deficit or cranial nerve palsy, and the patient’s intubation status. 12 
 13 
Results: In our cohort of 1787 consecutive patients, increasing patient age by 10 years and low pre-ictal 14 
functional status (mRS 3-5) were inversely correlated with “high" GCS score (GCS ≥13) (OR 0.91, 95%CI 0.84-15 
0.97 and OR 0.67, 95%CI 0.31-1.46), “low” WFNS grade (grade VI-V) (OR 1.21, 95%CI 1.04-1.20 and OR 16 
1.47, 95%CI 0.66-3.27), and “high” Fisher grade (grade III-IV) (OR 1.08, 95%CI 1.00-1.17 and OR 1.54, 17 
95%CI 0.55-4.32). Other independent predictors for the patients’ clinical and radiological condition at admission 18 
were the ruptured aneurysms’ location and its size.  19 
 20 
Conclusion: Patient age and pre-ictal functional status, as well as the ruptured aneurysm’s location and size 21 
determine the patients’ clinical and radiological condition at admission to the tertiary referral hospital.  22 
 23 
 24 
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 1 
Introduction 1 
 2 
Aneurysmal subarachnoid hemorrhage (aSAH) accounts for about 5% of strokes but has a disproportionate 3 
mortality rate of 40 to 60% [1-3]. Aneurysm characteristics such as location, size, and morphology govern an 4 
intracranial aneurysm’s tendency to bleed [4, 5], while outcome following aneurysm rupture is determined by 5 
factors that include patient age and severity of the bleed [6, 7]. In routine clinical practice, the severity of aSAH 6 
is assessed by a series of grading scales that yield objective measure of a patient’s clinical and radiological 7 
condition ad admission. These aSAH-specific indexes serve as to guide treatment decisions and for 8 
prognostication [8-10]. They include in particular the World Federation of Neurosurgical Societies (WFNS) 9 
classification [11] with the GCS score [12] as its main component [13]. In addition, radiological scores such as 10 
the Fisher grading scale [14] and the presence or absence of a thick blood clot on CT scan serve as to predict the 11 
risk of developing hydrocephalus and/or vasospasm with or without delayed cerebral ischemia (DCI) [15-17]. 12 
Although used in everyday practice, aSAH specific indexes were often based on poorly representative data from 13 
a today’s point of view, which may lead to conflicting results as to the nature and the extent of associations in 14 
contemporary Western populations defined by increased health condition and life expectancy [6, 18-22].  15 
 16 
The purpose of the present cohort study was to investigate what factors determine the patients’ clinical and 17 
radiological status at the time point of initial admission to the tertiary referral hospital in a representative Central 18 
European cohort of aSAH patients. Only few registries offer the combination of a dedicated nationwide all 19 
including registration of aSAH patients with highly detailed data acquisition that is not part of more general 20 
stroke registries [23-28]. The Swiss Study of Subarachnoid Hemorrhage (SOS) database provides the 21 
exceptional property that all aSAH in Switzerland are treated within one of the participating centers, hence to a 22 
certain extent representing the nations’ true epidemiology [29]. In sum, we expect our finding to apply 23 
eventually to all countries with typical aging demographics and with a similar health care system, meaning with 24 
universal access and coverage.  25 
 26 
 27 
 28 
Materials and Methods 29 
 30 
Patient registry  31 
Revised Manuscript (revisions marked in RED) Click here to download Manuscript Revised main document_Neurosurgical Review_ 25.01.2018.docx
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 2 
The SOS registry was implemented in 2009 and study details were previously published [29]. Internal Review 32 
Board and Ethical committee approval was obtained for all participating centers (under the supervision of the 33 
Geneva ethical committee board no. 11-233R, NAC 11-085R). Most local Ethic Committees waived the need for 34 
obtaining written informed consent (justification: disproportionality). Written informed consent was obtained 35 
however from all participating patients if the local Ethic Committee had requested it. As of 2014 36 
(implementation of the new Swiss Human Research Act), written informed consent was obtained from all 37 
participating patients in all participating centers. This study was a retrospective analysis of a prospectively 38 
collected database and does not require clinical trial registration.  39 
 40 
Study centers and data collection 41 
Patients with aSAH in Switzerland are cared for in one of the eight accredited neurovascular referral centers 42 
(university hospitals of Basel, Bern, Geneva, Lausanne, and Zurich, and the cantonal hospitals of Aarau, Lugano, 43 
and St. Gallen). All eight centers contributed data to the Swiss SOS registry [29]. Clinical and radiological 44 
assessment at admission was performed at each individual center with the center-specific standard procedures for 45 
the management and treatment of aSAH [30]. A predefined set of clinical and radiological variables were 46 
prospectively pooled in a secured, pseudonymized web-based registry for the present study (secuTrial®, 47 
InterActive Systems GmbH, Berlin, Germany) [29]. 48 
 49 
Study population  50 
Data was collected for all patients with aSAH from a documented ruptured intracranial aneurysm from 2009 to 51 
2014 that were admitted to one of the participating centers. Patients were excluded if they had non-aneurysmal 52 
SAH, an angiographically negative SAH, SAH of another confirmed cause, or no available information 53 
regarding the source of SAH.  54 
 55 
Study variables 56 
For the present study the following variables were extracted and anonymized from the SOS database: patient 57 
characteristics (age, gender, and pre-aSAH mRankin scale score (mRS) [31]), aneurysm characteristics 58 
(location and maximal diameter of the ruptured index aneurysm, aneurysm multiplicity), admission scores (GCS 59 
score, WFNS grade, Fisher grade), and additional variables (new neurological deficits (ND), new cranial nerve 60 
palsies (CNP), intubation status at admission, and presence of a thick cisternal or ventricular blood clot larger 61 
than 5 x 3 mm in the axial plane on the admission CT scan).  62 
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 3 
 63 
Endpoints 64 
The primary/co-primary endpoints were defined as the GCS score and the WFNS grade at the time point of 65 
initial admission to the tertiary referral hospital.  The secondary endpoints were defined as the Fisher grade, the 66 
presence or absence of a thick blood clot on admission CT scan, the presence or absence of a new neurological 67 
deficit or cranial nerve palsy on admission exam, and the patient’s intubation status at the time point of initial 68 
admission to the tertiary referral hospital.  69 
 70 
Statistical analysis 71 
Statistical analysis was performed with R (R Foundation for Statistical Computing. Release date 2014. R for 72 
Windows. Version 3.0.3. Vienna, Austria). For the multivariate mixed effect logistic regression model, 73 
univariate models were calculated to test for associations between the variable of interest and independent 74 
variables (see study variables above). For this purpose, data was dichotomized into „high” GCS score (GCS ≥ 75 
13) versus „low” GCS score (GCS ≤ 12), “high” WFNS grade (WFNS grade IV-V) versus “low” WFNS grade 76 
WFNS score (I-III), and “high” Fisher grade (III-IV) versus “low” Fisher grade (Fisher grade I-II). Covariates 77 
with a p-value ≤ .2 were included in an initial multivariate model and model selection based on likelihood ratio 78 
tests and the Akaike Information Criterion was performed to reduce the set of covariates. For confounder-79 
adjusted analysis, sex, pre-aSAH mRS, anterior vs. posterior circulation aneurysm, and a “center” variable were 80 
entered into either a cumulative or a logistic linear mixed model depending on the type of the outcome. To 81 
account for non-independence of the measurements of the same center, a random “center” intercept was included 82 
in the statistical models. For multiple testing, post-hoc testing was performed using Bonferroni-Holm[32] 83 
method. To account for missing values, all statistical models were computed for a dataset of complete cases, for 84 
each covariate univariate, and on an imputed dataset, for which it was assumed that the missing values were 85 
missing at random (MAR). Five imputed datasets were produced by generating a random forest for each, with a 86 
different value for the random forest number generator for each dataset (Nonparametric Missing Value 87 
Imputation using Random Forest, r: package missForest). Statistical models were then computed for each 88 
imputed dataset, and Rubin's rule was applied to combine the estimates. The complete correlation tables are 89 
provided in Suppl. Data Table 1. Forrest plots are provided in Suppl. Data Figure 1. Statistical significance 90 
was defined as p ≤ 0.05. 91 
 92 
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 4 
Results 94 
 95 
The locked SOS dataset 2009 - 2014 included 1787 patients. A detailed patient inclusion profile that specifies 96 
the number of patients assessed for each of the tested variables is provided in Figure 1.  97 
 98 
Baseline characteristics  99 
The mean age at ictus was 55.9 (SD ± 13.2) years. A majority of patients were in the age range 40 to 64 years. 100 
The sex ratio was 1.52 (F:M). Details are provided in Table 1.  101 
 102 
Cumulative empirical distributions  103 
The number of patients in each severity level of the different admission scores, broken down for different age 104 
groups (if applicable) in provided in Table 2. Overall, the proportion of patients with no pre-existing disability 105 
(mRS=0) decreased with increasing patient age while the proportion of patients with “no significant” or “slight” 106 
disability (mRS=1-2) simultaneously rose (Suppl. Data Figure 2A). Similarly, the proportion of patients who 107 
presented with a “high” GCS score and with a “high” WFNS grade decreased with increasing patient age. 108 
Nonetheless, more than half of patients older than 75 years had favorable clinical admission scores if the latter 109 
were defined as GCS 13-15 and WNFS I-III (Suppl. Data Figure 2B and 2C). With regard to the radiological 110 
scores, the proportional distribution of patients by Fisher grade remained about constant with increasing patient 111 
age (Suppl. Data Figure 2D).  112 
A summary breakdown of the aSAH causing aneurysms’ characteristics is provided in Table 3. Overall, more 113 
than three-quarters of the aSAH-causing aneurysms were located in the anterior (carotid) circulation- with 114 
ruptured anterior communicating artery (ACommA) aneurysms being the most frequent (n = 546/1787; 30.6%). 115 
The largest proportion of aneurysms was ≥7mm in maximal diameter (n = 717/1787: 40.1%). The proportion of 116 
patients who presented with a “high GCS score” and a “good WFNS grade” was lower in the posterior 117 
circulation aneurysm group (Figure 2A and 2B), and in those patients whose aneurysm was larger than 7mm in 118 
maximal diameter (Figure 3C and 3D).   119 
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 5 
 120 
Correlations 121 
Impact of patient characteristics: increasing patient age by steps of 10 years was correlated with “low” GCS 122 
score. A patient’s risk for presenting with a “low” GCS increasing by 10.5% per each 10 years of additional age. 123 
Increasing patient age by 10 years was also correlated with “low” WFNS grade, with “high” Fisher grade, with 124 
presence of a large blood clot, and with presence of ND. These findings remained significant after accounting for 125 
multiple testing (Table 4, Suppl. Data Table 1, Suppl. Data Figure 1). The impact of lower pre-ictal functional 126 
status largely paralleled the impact of increasing patient age. However, our study remained underpowered to 127 
estimate the effect (Suppl. Data Table 1).   128 
 129 
Impact of aneurysm characteristics: vertebral artery (VA) and basilar artery (BA) location were correlated with 130 
“low” GCS score and “low” WFNS grade, as well as with the intubation status “intubated”. In contrast, middle 131 
cerebral artery (MCA) location was correlated with “good” WFNS grade and with “high” Fisher grade. In 132 
addition, MCA location was correlated with presence of a ND, and with presence of a CNP. Aneurysm size 133 
≥7mm when compared to ≤5mm was correlated with “low” GCS score, with “low” WFNS grade, and with 134 
presence of a CNP. These findings remained significant after accounting for multiple testing (Table 4, Suppl. 135 
Data Table 1, Suppl. Data Figure1). 136 
 137 
 138 
Discussion 139 
 140 
While previous work focused on outcome analysis, the purpose of the present nationwide cohort-study was to 141 
investigate what factors determine the patients’ clinical and radiological status at the time point of initial 142 
admission to the tertiary referral hospital [7, 33]. In line with a previous report, we found that patient age and 143 
lower pre-ictal functional status were both independent predictors for worse clinical and radiological status at the 144 
time of  a patient’s initial admission to the tertiary neurovascular referral hospital [7]. In other words, they both 145 
independently predicted worse admission scores, which in turn foretells poor outcome following aSAH [8-10]. 146 
In contrast to previous work, we also modeled specific aneurysm-related prognostic factors including detailed 147 
aneurysm location and size [7]. We found that certain specific locations of the aSAH causing aneurysm 148 
particularly in the posterior circulation (e.g. VA and BA), as well as increasing aneurysm size (>7mm), were 149 
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 6 
additional independent predictors for worse clinical and radiological status at admission to the tertiary referral 150 
hospital (Table 4, Suppl. Data Table 1, Suppl. Data Figure 1). 151 
 152 
Further strengths of the present study include its comparatively large-scale dataset that was prospectively 153 
provider-collected, nationwide, and hence relatively unselected. This obviates to some extent coding errors, 154 
patient selection, and center-specific bias. In addition, data quality was high and statistical analysis was 155 
comprehensive and adjusted for relevant confounders, multiple testing, and missing values. Finally, reporting of 156 
data and results is in accordance to the principles of the STROBE statement to minimize the risk of unsaid bias. 157 
 158 
We found that the aSAH causing aneurysm’s location and size independently predicted the patients’ clinical and 159 
radiological condition at time point of admission to the tertiary referral hospital (Table 4, Suppl. Data Table 1, 160 
Suppl. Data Figure 1). Our results hence support the concept that aneurysm characteristics should be handled as 161 
key factors in any potential aSAH-specific outcome assessment tool [6, 18, 34]. That being said, increasing 162 
patient age and pre-existing medical conditions have alike been identified as independent predictors for worse 163 
outcome following aSAH [7, 21, 33, 35-38]. Several attempts have been made over the year to integrate these 164 
elements into indexes so as to enhance the ability and the accuracy to predicting the course of the disease (e.g. 165 
Charlson comorbidity index [39, 40], SAH [41], FOUR-score [42]). Accordingly, we found in our cohort that the 166 
older was a patient, the lower was his pre-ictal functional status, and the more likely he presented in poor 167 
condition following aSAH (Table 4, Suppl. Data Table 1, Suppl. Data Figure 1). This being the case, the age 168 
at which patients develop a substantial decline in functional status has shifted from around age 50 a decade ago 169 
[43], to 60-65 years [7, 44-48], to 70-75 more recently [49] as well as in the present cohort (Table 1).  170 
 171 
The question still remains whether there is an age beyond which prognosis become decisively worse [43, 44, 48-172 
52], which means for instance that active aneurysm treatment might be withheld in all patients older than that 173 
cut-off age [53, 54]. We found in our cohort that for instance about half of patients older than 75 years had 174 
favorable outcome-predicting WFNS scores (Suppl. Data Figure 2B). We hence agree that active treatment 175 
should probably not be refused solely on the basis of advanced age [7], but instead suggest that chronological 176 
age be taken into consideration along with the patient’s pre-ictal functional status when making management and 177 
for prognostication [7, 19, 21, 33, 36, 37, 55-58].  178 
 179 
Limitations 180 
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Although there is a policy in Switzerland to transfer all aSAH patients to one of the accredited neurovascular 181 
centers that participate in the SOS registry, in practice, a fraction of patients may not end up in these centers (e.g. 182 
because they die at the admitting hospital from devastating brain hemorrhage of unclear etiology). However, the 183 
purpose of this study was not to assess outcome after aSAH, but to determine what factors influence a patient’s 184 
clinical and radiological status once admitted to a tertiary referral hospital. Besides that, risk factors and co-185 
morbidities such as cigarette smoking and arterial hypertension were not included into our analysis mainly 186 
because of missing values in our dataset. However, their influence has been studied elsewhere [59, 60]. Data 187 
quality was comparatively high. Still, there was missing data in our dataset. We compared the results of our 188 
regression models with pooled estimates obtained from imputed datasets to reduce the variability of the 189 
estimates in our multivariate analysis as well as to investigate whether missing values had introduced bias. We 190 
found that there was no relevant difference between coefficients estimated from imputed datasets and those 191 
estimated from the dataset restricted to complete cases. Finally, multivariate analyses concerning the impact of 192 
the pre-ictal mRS found associations, but ultimately lacked the necessary power to estimate the effect. This 193 
indicates more statistical power is eventually needed, and we suggest that in future study cohorts from countries 194 
with similar populations and similar treatment standards be merged to obtain valuable additional patients. 195 
 196 
 197 
Conclusions 198 
 199 
Chronological age should be considered when managing aSAH-patients along with multiple other aspects that 200 
include aneurysm location, aneurysm size, and pre-ictal functional status that all influence the patients’ clinical 201 
and radiological condition at admission, and hence the likely course of the disease. However, further research 202 
and even larger datasets will be required to determine the extent of associations in representative contemporary 203 
aSAH populations.  204 
 205 
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 237 
Appendix: Swiss SOS Study Group 238 
 239 
Members or collaborators of the Swiss SOS Study Group that were not listed as authors include: Javier Fandino, 240 
Daniel Colluccia, Marta Arrighi, Alice Venier, Dominique E. Kuhlen, Michael Reinert, Astrid Weyerbrock, 241 
Martin Hlavica, Jean-Yves Fournier, Andreas Raabe, Juergen Beck, David Bervini, Karl Schaller, Roy T. 242 
Daniel, Daniele Starnoni, Mahmoud Messerer, Marc Levivier, Emanuela Keller, Luca Regli, Oliver Bozinov, 243 
Sina Finkenstaedt, Luca Remonda, Christoph Stippich, Jan Gralla, Zsolt Kulcsar, Vitor Mendes-Pereira, 244 
Alessandro Cianfoni, Peter Ahlborn, Nicolas R. Smoll, Veit Rohde, Sina Tok, Fabian Baumann, Karl Kothbauer, 245 
Hassen Kerkeni, Hiroki Dan-Ura, Hans Landolt, Khaled Mostaguir, Yvan Gasche, Asita Sarrafzadeh, Gerhard 246 
Hildebrandt, Kerstin Winkler, Christoph Woernle, and Rene Bernays. 247 
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Figures 457 
 458 
 459 
Figure 1: Patient inclusion profile. 460 
 461 
Figure 2: Empirical cumulative distribution. 462 
A) Cumulative GCS distribution by index aneurysm location. B) Cumulative WFNS grade distribution by index 463 
aneurysm locations. C) Cumulative GCS grade distribution by index aneurysm size (maximal diameter in 464 
millimeters). D) Cumulative WFNS grade distribution by index aneurysm size (maximal diameter in 465 
millimeters). Remark: ACommA: anterior communicating artery; ACA: anterior cerebral artery; ICA: internal 466 
carotid artery; MCA: middle cerebral artery; PCommA: posterior communicating artery; PCA: posterior cerebral 467 
artery; BA: basilar artery; VA: vertebral artery; VBSB: vertebrobasilar side-branches including the superior 468 
cerebellar artery (SCA), the anterior inferior cerebellar artery (AICA), and the posterior inferior cerebellar artery 469 
(PICA).    470 
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 1 
Introduction 1 
 2 
Aneurysmal subarachnoid hemorrhage (aSAH) accounts for about 5% of strokes but has a disproportionate 3 
mortality rate of 40 to 60% [1-3]. Aneurysm characteristics such as location, size, and morphology govern an 4 
intracranial aneurysm’s tendency to bleed [4, 5], while outcome following aneurysm rupture is determined by 5 
factors that include patient age and severity of the bleed [6, 7]. In routine clinical practice, the severity of aSAH 6 
is assessed by a series of grading scales that yield objective measure of a patient’s clinical and radiological 7 
condition ad admission. These aSAH-specific indexes serve as to guide treatment decisions and for 8 
prognostication [8-10]. They include in particular the World Federation of Neurosurgical Societies (WFNS) 9 
classification [11] with the GCS score [12] as its main component [13]. In addition, radiological scores such as 10 
the Fisher grading scale [14] and the presence or absence of a thick blood clot on CT scan serve as to predict the 11 
risk of developing hydrocephalus and/or vasospasm with or without delayed cerebral ischemia (DCI) [15-17]. 12 
Although used in everyday practice, aSAH specific indexes were often based on poorly representative data from 13 
a today’s point of view, which may lead to conflicting results as to the nature and the extent of associations in 14 
contemporary Western populations defined by increased health condition and life expectancy [6, 18-22].  15 
 16 
The purpose of the present cohort study was to investigate what factors determine the patients’ clinical and 17 
radiological status at the time point of initial admission to the tertiary referral hospital in a representative Central 18 
European cohort of aSAH patients. Only few registries offer the combination of a dedicated nationwide all 19 
including registration of aSAH patients with highly detailed data acquisition that is not part of more general 20 
stroke registries [23-28]. The Swiss Study of Subarachnoid Hemorrhage (SOS) database provides the 21 
exceptional property that all aSAH in Switzerland are treated within one of the participating centers, hence to a 22 
certain extent representing the nations’ true epidemiology [29]. In sum, we expect our finding to apply 23 
eventually to all countries with typical aging demographics and with a similar health care system, meaning with 24 
universal access and coverage.  25 
 26 
 27 
 28 
Materials and Methods 29 
 30 
Patient registry  31 
Revised Manuscript (clean version) Click here to download Manuscript Clean revised document_Neurosurgical Review_ 25.01.2018.docx
Click here to view linked References
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The SOS registry was implemented in 2009 and study details were previously published [29]. Internal Review 32 
Board and Ethical committee approval was obtained for all participating centers (under the supervision of the 33 
Geneva ethical committee board no. 11-233R, NAC 11-085R). Most local Ethic Committees waived the need for 34 
obtaining written informed consent (justification: disproportionality). Written informed consent was obtained 35 
however from all participating patients if the local Ethic Committee had requested it. As of 2014 36 
(implementation of the new Swiss Human Research Act), written informed consent was obtained from all 37 
participating patients in all participating centers. This study was a retrospective analysis of a prospectively 38 
collected database and does not require clinical trial registration.  39 
 40 
Study centers and data collection 41 
Patients with aSAH in Switzerland are cared for in one of the eight accredited neurovascular referral centers 42 
(university hospitals of Basel, Bern, Geneva, Lausanne, and Zurich, and the cantonal hospitals of Aarau, Lugano, 43 
and St. Gallen). All eight centers contributed data to the Swiss SOS registry [29]. Clinical and radiological 44 
assessment at admission was performed at each individual center with the center-specific standard procedures for 45 
the management and treatment of aSAH [30]. A predefined set of clinical and radiological variables were 46 
prospectively pooled in a secured, pseudonymized web-based registry for the present study (secuTrial®, 47 
InterActive Systems GmbH, Berlin, Germany) [29]. 48 
 49 
Study population  50 
Data was collected for all patients with aSAH from a documented ruptured intracranial aneurysm from 2009 to 51 
2014 that were admitted to one of the participating centers. Patients were excluded if they had non-aneurysmal 52 
SAH, an angiographically negative SAH, SAH of another confirmed cause, or no available information 53 
regarding the source of SAH.  54 
 55 
Study variables 56 
For the present study the following variables were extracted and anonymized from the SOS database: patient 57 
characteristics (age, gender, and pre-aSAH mRankin scale score (mRS) [31]), aneurysm characteristics 58 
(location and maximal diameter of the ruptured index aneurysm, aneurysm multiplicity), admission scores (GCS 59 
score, WFNS grade, Fisher grade), and additional variables (new neurological deficits (ND), new cranial nerve 60 
palsies (CNP), intubation status at admission, and presence of a thick cisternal or ventricular blood clot larger 61 
than 5 x 3 mm in the axial plane on the admission CT scan).  62 
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 63 
Endpoints 64 
The primary/co-primary endpoints were defined as the GCS score and the WFNS grade at the time point of 65 
initial admission to the tertiary referral hospital.  The secondary endpoints were defined as the Fisher grade, the 66 
presence or absence of a thick blood clot on admission CT scan, the presence or absence of a new neurological 67 
deficit or cranial nerve palsy on admission exam, and the patient’s intubation status at the time point of initial 68 
admission to the tertiary referral hospital.  69 
 70 
Statistical analysis 71 
Statistical analysis was performed with R (R Foundation for Statistical Computing. Release date 2014. R for 72 
Windows. Version 3.0.3. Vienna, Austria). For the multivariate mixed effect logistic regression model, 73 
univariate models were calculated to test for associations between the variable of interest and independent 74 
variables (see study variables above). For this purpose, data was dichotomized into „high” GCS score (GCS ≥ 75 
13) versus „low” GCS score (GCS ≤ 12), “high” WFNS grade (WFNS grade IV-V) versus “low” WFNS grade 76 
WFNS score (I-III), and “high” Fisher grade (III-IV) versus “low” Fisher grade (Fisher grade I-II). Covariates 77 
with a p-value ≤ .2 were included in an initial multivariate model and model selection based on likelihood ratio 78 
tests and the Akaike Information Criterion was performed to reduce the set of covariates. For confounder-79 
adjusted analysis, sex, pre-aSAH mRS, anterior vs. posterior circulation aneurysm, and a “center” variable were 80 
entered into either a cumulative or a logistic linear mixed model depending on the type of the outcome. To 81 
account for non-independence of the measurements of the same center, a random “center” intercept was included 82 
in the statistical models. For multiple testing, post-hoc testing was performed using Bonferroni-Holm[32] 83 
method. To account for missing values, all statistical models were computed for a dataset of complete cases, for 84 
each covariate univariate, and on an imputed dataset, for which it was assumed that the missing values were 85 
missing at random (MAR). Five imputed datasets were produced by generating a random forest for each, with a 86 
different value for the random forest number generator for each dataset (Nonparametric Missing Value 87 
Imputation using Random Forest, r: package missForest). Statistical models were then computed for each 88 
imputed dataset, and Rubin's rule was applied to combine the estimates. The complete correlation tables are 89 
provided in Suppl. Data Table 1. Forrest plots are provided in Suppl. Data Figure 1. Statistical significance 90 
was defined as p ≤ 0.05. 91 
 92 
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 4 
Results 94 
 95 
The locked SOS dataset 2009 - 2014 included 1787 patients. A detailed patient inclusion profile that specifies 96 
the number of patients assessed for each of the tested variables is provided in Figure 1.  97 
 98 
Baseline characteristics  99 
The mean age at ictus was 55.9 (SD ± 13.2) years. A majority of patients were in the age range 40 to 64 years. 100 
The sex ratio was 1.52 (F:M). Details are provided in Table 1.  101 
 102 
Cumulative empirical distributions  103 
The number of patients in each severity level of the different admission scores, broken down for different age 104 
groups (if applicable) in provided in Table 2. Overall, the proportion of patients with no pre-existing disability 105 
(mRS=0) decreased with increasing patient age while the proportion of patients with “no significant” or “slight” 106 
disability (mRS=1-2) simultaneously rose (Suppl. Data Figure 2A). Similarly, the proportion of patients who 107 
presented with a “high” GCS score and with a “high” WFNS grade decreased with increasing patient age. 108 
Nonetheless, more than half of patients older than 75 years had favorable clinical admission scores if the latter 109 
were defined as GCS 13-15 and WNFS I-III (Suppl. Data Figure 2B and 2C). With regard to the radiological 110 
scores, the proportional distribution of patients by Fisher grade remained about constant with increasing patient 111 
age (Suppl. Data Figure 2D).  112 
A summary breakdown of the aSAH causing aneurysms’ characteristics is provided in Table 3. Overall, more 113 
than three-quarters of the aSAH-causing aneurysms were located in the anterior (carotid) circulation- with 114 
ruptured anterior communicating artery (ACommA) aneurysms being the most frequent (n = 546/1787; 30.6%). 115 
The largest proportion of aneurysms was ≥7mm in maximal diameter (n = 717/1787: 40.1%). The proportion of 116 
patients who presented with a “high GCS score” and a “good WFNS grade” was lower in the posterior 117 
circulation aneurysm group (Figure 2A and 2B), and in those patients whose aneurysm was larger than 7mm in 118 
maximal diameter (Figure 3C and 3D).   119 
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 120 
Correlations 121 
Impact of patient characteristics: increasing patient age by steps of 10 years was correlated with “low” GCS 122 
score. A patient’s risk for presenting with a “low” GCS increasing by 10.5% per each 10 years of additional age. 123 
Increasing patient age by 10 years was also correlated with “low” WFNS grade, with “high” Fisher grade, with 124 
presence of a large blood clot, and with presence of ND. These findings remained significant after accounting for 125 
multiple testing (Table 4, Suppl. Data Table 1, Suppl. Data Figure 1). The impact of lower pre-ictal functional 126 
status largely paralleled the impact of increasing patient age. However, our study remained underpowered to 127 
estimate the effect (Suppl. Data Table 1).   128 
 129 
Impact of aneurysm characteristics: vertebral artery (VA) and basilar artery (BA) location were correlated with 130 
“low” GCS score and “low” WFNS grade, as well as with the intubation status “intubated”. In contrast, middle 131 
cerebral artery (MCA) location was correlated with “good” WFNS grade and with “high” Fisher grade. In 132 
addition, MCA location was correlated with presence of a ND, and with presence of a CNP. Aneurysm size 133 
≥7mm when compared to ≤5mm was correlated with “low” GCS score, with “low” WFNS grade, and with 134 
presence of a CNP. These findings remained significant after accounting for multiple testing (Table 4, Suppl. 135 
Data Table 1, Suppl. Data Figure1). 136 
 137 
 138 
Discussion 139 
 140 
While previous work focused on outcome analysis, the purpose of the present nationwide cohort-study was to 141 
investigate what factors determine the patients’ clinical and radiological status at the time point of initial 142 
admission to the tertiary referral hospital [7, 33]. In line with a previous report, we found that patient age and 143 
lower pre-ictal functional status were both independent predictors for worse clinical and radiological status at the 144 
time of  a patient’s initial admission to the tertiary neurovascular referral hospital [7]. In other words, they both 145 
independently predicted worse admission scores, which in turn foretells poor outcome following aSAH [8-10]. 146 
In contrast to previous work, we also modeled specific aneurysm-related prognostic factors including detailed 147 
aneurysm location and size [7]. We found that certain specific locations of the aSAH causing aneurysm 148 
particularly in the posterior circulation (e.g. VA and BA), as well as increasing aneurysm size (>7mm), were 149 
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 6 
additional independent predictors for worse clinical and radiological status at admission to the tertiary referral 150 
hospital (Table 4, Suppl. Data Table 1, Suppl. Data Figure 1). 151 
 152 
Further strengths of the present study include its comparatively large-scale dataset that was prospectively 153 
provider-collected, nationwide, and hence relatively unselected. This obviates to some extent coding errors, 154 
patient selection, and center-specific bias. In addition, data quality was high and statistical analysis was 155 
comprehensive and adjusted for relevant confounders, multiple testing, and missing values. Finally, reporting of 156 
data and results is in accordance to the principles of the STROBE statement to minimize the risk of unsaid bias. 157 
 158 
We found that the aSAH causing aneurysm’s location and size independently predicted the patients’ clinical and 159 
radiological condition at time point of admission to the tertiary referral hospital (Table 4, Suppl. Data Table 1, 160 
Suppl. Data Figure 1). Our results hence support the concept that aneurysm characteristics should be handled as 161 
key factors in any potential aSAH-specific outcome assessment tool [6, 18, 34]. That being said, increasing 162 
patient age and pre-existing medical conditions have alike been identified as independent predictors for worse 163 
outcome following aSAH [7, 21, 33, 35-38]. Several attempts have been made over the year to integrate these 164 
elements into indexes so as to enhance the ability and the accuracy to predicting the course of the disease (e.g. 165 
Charlson comorbidity index [39, 40], SAH [41], FOUR-score [42]). Accordingly, we found in our cohort that the 166 
older was a patient, the lower was his pre-ictal functional status, and the more likely he presented in poor 167 
condition following aSAH (Table 4, Suppl. Data Table 1, Suppl. Data Figure 1). This being the case, the age 168 
at which patients develop a substantial decline in functional status has shifted from around age 50 a decade ago 169 
[43], to 60-65 years [7, 44-48], to 70-75 more recently [49] as well as in the present cohort (Table 1).  170 
 171 
The question still remains whether there is an age beyond which prognosis become decisively worse [43, 44, 48-172 
52], which means for instance that active aneurysm treatment might be withheld in all patients older than that 173 
cut-off age [53, 54]. We found in our cohort that for instance about half of patients older than 75 years had 174 
favorable outcome-predicting WFNS scores (Suppl. Data Figure 2B). We hence agree that active treatment 175 
should probably not be refused solely on the basis of advanced age [7], but instead suggest that chronological 176 
age be taken into consideration along with the patient’s pre-ictal functional status when making management and 177 
for prognostication [7, 19, 21, 33, 36, 37, 55-58].  178 
 179 
Limitations 180 
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 7 
Although there is a policy in Switzerland to transfer all aSAH patients to one of the accredited neurovascular 181 
centers that participate in the SOS registry, in practice, a fraction of patients may not end up in these centers (e.g. 182 
because they die at the admitting hospital from devastating brain hemorrhage of unclear etiology). However, the 183 
purpose of this study was not to assess outcome after aSAH, but to determine what factors influence a patient’s 184 
clinical and radiological status once admitted to a tertiary referral hospital. Besides that, risk factors and co-185 
morbidities such as cigarette smoking and arterial hypertension were not included into our analysis mainly 186 
because of missing values in our dataset. However, their influence has been studied elsewhere [59, 60]. Data 187 
quality was comparatively high. Still, there was missing data in our dataset. We compared the results of our 188 
regression models with pooled estimates obtained from imputed datasets to reduce the variability of the 189 
estimates in our multivariate analysis as well as to investigate whether missing values had introduced bias. We 190 
found that there was no relevant difference between coefficients estimated from imputed datasets and those 191 
estimated from the dataset restricted to complete cases. Finally, multivariate analyses concerning the impact of 192 
the pre-ictal mRS found associations, but ultimately lacked the necessary power to estimate the effect. This 193 
indicates more statistical power is eventually needed, and we suggest that in future study cohorts from countries 194 
with similar populations and similar treatment standards be merged to obtain valuable additional patients. 195 
 196 
 197 
Conclusions 198 
 199 
Chronological age should be considered when managing aSAH-patients along with multiple other aspects that 200 
include aneurysm location, aneurysm size, and pre-ictal functional status that all influence the patients’ clinical 201 
and radiological condition at admission, and hence the likely course of the disease. However, further research 202 
and even larger datasets will be required to determine the extent of associations in representative contemporary 203 
aSAH populations.  204 
 205 
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 236 
 237 
Appendix: Swiss SOS Study Group 238 
 239 
Members or collaborators of the Swiss SOS Study Group that were not listed as authors include: Javier Fandino, 240 
Daniel Colluccia, Marta Arrighi, Alice Venier, Dominique E. Kuhlen, Michael Reinert, Astrid Weyerbrock, 241 
Martin Hlavica, Jean-Yves Fournier, Andreas Raabe, Juergen Beck, David Bervini, Karl Schaller, Roy T. 242 
Daniel, Daniele Starnoni, Mahmoud Messerer, Marc Levivier, Emanuela Keller, Luca Regli, Oliver Bozinov, 243 
Sina Finkenstaedt, Luca Remonda, Christoph Stippich, Jan Gralla, Zsolt Kulcsar, Vitor Mendes-Pereira, 244 
Alessandro Cianfoni, Peter Ahlborn, Nicolas R. Smoll, Veit Rohde, Sina Tok, Fabian Baumann, Karl Kothbauer, 245 
Hassen Kerkeni, Hiroki Dan-Ura, Hans Landolt, Khaled Mostaguir, Yvan Gasche, Asita Sarrafzadeh, Gerhard 246 
Hildebrandt, Kerstin Winkler, Christoph Woernle, and Rene Bernays. 247 
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Figures 457 
 458 
 459 
Figure 1: Patient inclusion profile. 460 
 461 
Figure 2: Empirical cumulative distribution. 462 
A) Cumulative GCS distribution by index aneurysm location. B) Cumulative WFNS grade distribution by index 463 
aneurysm locations. C) Cumulative GCS grade distribution by index aneurysm size (maximal diameter in 464 
millimeters). D) Cumulative WFNS grade distribution by index aneurysm size (maximal diameter in 465 
millimeters). Remark: ACommA: anterior communicating artery; ACA: anterior cerebral artery; ICA: internal 466 
carotid artery; MCA: middle cerebral artery; PCommA: posterior communicating artery; PCA: posterior cerebral 467 
artery; BA: basilar artery; VA: vertebral artery; VBSB: vertebrobasilar side-branches including the superior 468 
cerebellar artery (SCA), the anterior inferior cerebellar artery (AICA), and the posterior inferior cerebellar artery 469 
(PICA).    470 
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Study Population 
(n) 
 
1787 
  
 
Age at admission 
 
Total 
 
Females 
 
Males 
 (mean) 55.9 years  (SD ± 13.2) 57 years 53.7 years 
 
Age groups n (%) n (%) n (%) 
0 - 39 years 202 (11.3) 108 (9.2) 94 (15.3) 
40 - 64 years 1175 (65.5) 764 (64.9) 409 (66.7) 
65 - 74 years 264 (14.7) 191 (16.2) 73 (11.9) 
≥75 years 152 (8.5) 115 (9.8) 37 (6.0) 
 
Table 1: Baseline characteristics 
Table 1 Click here to download Table Table 1.docx 
  
Total Age 0-40yrs Age 40-65yrs Age 65-75yrs Age ≥75yrs 
  n (%) n (%) n (%) n (%) n (%) 
Pre-SAH mRS 
mRS 0 1392 (77.9) 171 (95) 935 (89) 195 (82.3) 91 (65.5) 
mRS 1-2 193 (10.8) 8 (4.4) 105 (10) 39 (16.5) 41 (29.5) 
mRS 3-5 21 (1.2) 1 (0.6) 10 (1) 3 (1.2) 7 (5) 
Missing* 181 (10.1)     
Total 1787 (100) 180 (11.2) 1050 (65.4) 237 (14.8) 139 (8.7) 
      
GCS       
GCS 3-6 485 (27.5) 45 (22.5) 304 (26.6) 95 (35.7) 41 (26.6) 
GCS 7-12 190 (10.8) 15 (7.5) 121 (10.6) 31 (11.7) 23 (14.9) 
GCS 13-15 1090 (61.8) 140 (70) 720 (62.9) 140 (52.6) 90 (58.4) 
Missing* 22 (1.2)  
      
Total  1765 (100) 200 (11.3) 1145 (64.9) 266 (15.1) 154 (8.7) 
     
WFNS grade      
I-III 1104 (62.3) 140 (70) 729 (63.4) 142 (53.2) 93 (60.4) 
IV-V 667 (37.7) 60 (30) 421 (36.6) 125 (46.8) 61 (39.6) 
Missing* 16 (0.9)     
Total 1771 (100) 200 (11.3) 1150 (64.9) 267 (15.1) 154 (8.7) 
      
Fisher grade        
I 54 (3.0)      
II 163 (9.1)   
III 989 (55.3)  
IV 
Missing* 
576 (32.5) 
5 (0.3) 
 
 
 
 
 
 
 
 
 
Neurological 
deficit  
n (%) 
Cranial nerve 
palsy  
n (%) 
Thick blood clot 
 
 n (%) 
Intubated  
 
n (%) 
 
Yes 453 (27.1) 345 (20.7) 1565 (87.6) 389 (31.9) 
 
Missing* 123 (6.9) 83 (4.6) 4 (0.2) 567 (31.7) 
 
 
 
Table 2: Admission scores  
Age group-related number of patients in each severity level of the different admission scores 
*No information available  
Table 2 Click here to download Table Table 2.docx 
 Aneurysm size distribution Total <5mm 5-<7mm ≥7mm Missing* 
n (%) n (%)    n (%)   n (%) 
  n (%) 
 
Anterior (carotid) circulation 1479 (82.8) 420 (28.4) 367 (24.8) 623 (42.1) 69 (4.7) 
Posterior (vertebrobasilar) circulation  250 (14.0) 79 (31.6) 59 (23.6) 94 (37.6) 18 (7.2) 
Missing* 58 (3.2) 1 (1.7) 0 (0) 0(0) 57 (98.3) 
Total 1787 (100) 500 (28) 426 (23.8) 717 (40) 144 (8.1) 
 
Table 3: Frequency table. 
Remark: A detailed breakdown of aneurysms by size and by location will be published separately. 
*No information available  
 
Table 3 Click here to download Table Table3.docx 
 Roethlisberger, Zumofen, Guzman et al. (19.09.2017) 1 
 
  MV OR p-values CI (95 %)  UV OR p-values CI (95 %)  IMP OR p-values CI (95 %) 
 
High GCS score 
Age  0.91 0.006 0.84 - 0.97  0.90 0.001 0.84 - 0.96  0.91 0.003 0.85 - 0.97 
MCA  0.78 0.053 0.60 - 1.00  0.75 0.014 0.59 - 0.94  0.76 0.027 0.60 - 0.97 
VA  0.32 0.002 0.15 - 0.65  0.34 0.001 0.19 - 0.63  0.36 0.001 0.20 - 0.66 
BA  0.58 0.011 0.38 - 0.89  0.56 0.003 0.39 - 0.83  0.58 0.006 0.39 - 0.86 
PICA / AICA / SCA 0.61 0.027 0.40 - 0.95  0.70 0.077 0.47 - 1.04  0.68 0.057 0.46 - 1.01 
> 7 mm   0.66 <0.001 0.52 - 0.82  0.69 0.001 0.56 - 0.85  0.69 0.001 0.55 - 0.86 
 
High WFNS score  
Age  1.12 0.003 1.04 - 1.10  1.12 <0.001 1.05 - 1.20  1.11 0.002 1.04 - 1.19 
MCA  1.33 0.031 1.02 - 1.72  1.36 0.010 1.09 - 1.72  1.33 0.019 1.05 - 1.69 
VA  3.09 0.002 1.50 - 6.35  2.89 0.001 1.57 - 5.32  2.64 0.002 1.44 - 4.83 
BA  1.72 0.012 1.13 - 2.61  1.70 0.008 1.15 - 2.51  1.64 0.014 1.12 - 2.43 
PICA / AICA / SCA 1.62 0.030 1.05 - 2.50  1.43 0.077 0.96 - 2.14  1.47 0.063 0.98 - 2.19 
> 7 mm   1.54 <0.001 1.23 - 1.93  1.45 <0.001 1.18 - 1.79  1.47 0.001 1.18 - 1.83 
 
High Fisher grade (grade III – IV) 
Age  1.09 0.044 1.00 - 1.17  1.09 0.018 1.01 - 1.17  1.08 0.042 1.00 - 1.16 
MCA  1.39 0.025 1.04 - 1.85  1.25 0.091 0.97 - 1.62  1.22 0.139 0.94 - 1.60 
 
New focal neurological deficit 
Age  1.12 0.016 1.02 - 1.24  1.10 0.033 1.01 - 1.19  1.11 0.024 1.02 - 1.20 
MCA  2.17 <0.001 1.56 - 3.03  2.11 <0.001 1.56 - 2.86  2.02 <0.001 1.49 - 2.73 
PCA  2.53 0.049 1.00 - 6.40  2.13 0.098 0.87 - 5.19  2.25 0.072 0.92 - 5.49 
 
New cranial nerve palsy 
ICA  1.62 0.026 1.06 - 2.47  1.73 0.005 1.18 - 2.52  1.56 0.019 1.08 - 2.26 
MCA  1.92 0.001 1.31 - 2.81  2.08 <0.001 1.48 - 2.92  1.84 0.001 1.30 - 2.58 
> 7 mm   1.76 0.001 1.20 - 2.48  1.77 <0.001 1.30 - 2.42  1.64 0.003 1.19 - 2.25 
 
Thick clot present  
Age  1.21     0.002    1.07 - 1.36  1.16 0.009   1.04 - 1.29  1.18     0.003    1.06 - 1.32 
 
Sedated at admission 
VA  3.17 0.020 1.20 - 8.39  3.40 0.003 1.52 - 7.61  3.21  0.002    1.53 - 6.74 
> 7 mm   1.45 0.032 1.03 - 2.03  1.38 0.037 1.02 - 1.88  1.49 0.038    1.08 - 2.06 
 
Intubed at admission 
BA  1.88 0.046 1.01 - 3.50  1.84 0.030 1.06 - 3.19  1.58 0.100 0.94 - 2.64 
VA  3.04 0.025 1.15 - 8.02  3.27 0.004 1.46 - 7.32  2.85 0.003 1.43 - 5.67 
> 7 mm   1.51 0.017 1.08 - 2.11  1.45 0.015 1.08 - 1.96  1.59 0.002 1.22 - 2.09 
 
 
Table 4: Correlation tables.   
Correlation tables of multivariate analysis [MV], univariate analysis [UV] and analysis of imputed data of 
missing values [IMP] for correlations with p-value < 0.5. Data was dichotomized into „high” GCS score (GCS ≥ 
13) versus „low” GCS score (GCS ≤ 12), “high” WFNS grade (WFNS grade IV-V) versus “low” WFNS grade 
Table 4 Click here to download Table Table 4.docx 
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WFNS score (I-III), and “high” Fisher grade (III-IV) versus “low” Fisher grade (Fisher grade I-II). Details are 
provided in Suppl. Data Table 1. Forest plots are provided in Suppl. Data Figure 1.  
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Figure 2A Click here to download Figure Figure 2A 
Figure 2B Click here to download Figure Figure 2B 
Figure 2C Click here to download Figure Figure 2C 
Figure 2D Click here to download Figure Figure 2D 
  
Multivariate analysis [MV], univariate analysis [UV] and analysis of imputed data of missing values [IMP] 
Odds ratio for ͞high͟ Glasgow coŵa score [GCS] 
 
Variable  MV OR p-values CI (95 %)  UV OR p-values CI (95 %)  IMP OR p-values CI (95 %) 
 
Age  0.91 0.006 0.84 - 0.97  0.90 0.001 0.84 - 0.96  0.91 0.003 0.85 - 0.97 
Sex  1.02 0.876 0.83 - 1.25  1.14 0.150 0.95 - 1.36  1.02 0.324 0.90 - 1.32 
Pre-SAH mRankin  
Scale 1-2  0.97 0.851 0.71 - 1.32  0.87 0.354 0.65 - 1.17  0.92 0.435 0.69 - 1.24 
Pre-SAH mRankin 
Scale 3-5  0.67 0.317 0.31 - 1.46  0.57 0.122 0.28 - 1.16  0.62 0.184 0.30 - 1.27 
ICA  0.87 0.325 0.65 - 1.15  0.84 0.199 0.65 - 1.01  0.89 0.382 0.68 - 1.16  
MCA  0.78 0.053 0.60 - 1.00  0.75 0.014 0.59 - 0.94  0.76 0.027 0.60 - 0.97 
ACA  0.87 0.480 0.58 - 1.29  0.96 0.812 0.67 - 1.37  0.91 0.603 0.61 - 1.31 
PComm  1.20 0.351 0.82 - 1.76  1.08 0.661 0.76 - 1.54  1.20 0.315 0.84 - 1.72 
VA  0.32 0.002 0.15 - 0.65  0.34 0.001 0.19 - 0.63  0.36 0.001 0.20 - 0.66 
BA  0.58 0.011 0.38 - 0.89  0.56 0.003 0.39 - 0.83  0.58 0.006 0.39 - 0.86 
PICA / AICA / SCA 0.61 0.027 0.40 - 0.95  0.70 0.077 0.47 - 1.04  0.68 0.057 0.46 - 1.01 
PCA  0.55 0.127 0.25 - 1.19  0.56 0.114 0.27 - 1.15  0.59 0.119 0.27 - 1.16 
Unknown  1.15 0.927 0.06 - 21.8  0.94 0.806 0.55 - 1.59  0.98 0.839 0.57 - 1.67 
< 7 mm   0.84 0.154 0.65 - 1.07  0.89 0.309 0.70 - 1.12  0.85 0.181 0.67 - 1.07 
> 7 mm   0.66 <0.001 0.52 - 0.82  0.69 0.001 0.56 - 0.85  0.69 0.001 0.55 - 0.86 
 
 
Odds ratio for ͞high͟ World FederatioŶ of Neurological SurgeoŶs [WFNS] score 
 
Variable  MV OR p-values CI (95 %)  UV OR p-values CI (95 %)  IMP OR p-values CI (95 %) 
 
Age  1.12 0.003 1.04 - 1.10  1.12 <0.001 1.05 - 1.20  1.11 0.002 1.04 - 1.19 
Sex  0.92 0.429 0.75 - 1.13  0.84 0.052 0.70 - 1.00  0.87 0.149 0.72 - 1.05 
Pre-SAH mRankin  
Scale 1-2  1.08 0.603 0.80 - 1.47  1.21 0.208 0.90 - 1.62  1.10 0.401 0.81 - 1.48 
Pre-SAH mRankin 
Scale 3-5  1.47 0.341 0.66 - 3.27  1.68 0.161 0.81 - 3.48  1.58 0.239 0.73 - 3.46 
ICA  1.22 0.180 0.91 - 1.63  1.24 0.109 0.95 - 1.62  1.18 0.241 0.90 - 1.54 
MCA  1.33 0.031 1.02 - 1.72  1.36 0.010 1.09 - 1.72  1.33 0.019 1.05 - 1.69 
ACA  1.22 0.319 0.82 - 1.82  1.09 0.635 0.76 - 1.57  1.15 0.442 0.80 - 1.67 
PComm  0.88 0.524 0.60 - 1.29  0.97 0.879 0.69 - 1.38  0.86 0.411 0.60 - 1.23 
VA  3.09 0.002 1.50 - 6.35  2.89 0.001 1.57 - 5.32  2.64 0.002 1.44 - 4.83 
BA  1.72 0.012 1.13 - 2.61  1.70 0.008 1.15 - 2.51  1.64 0.014 1.12 - 2.43 
PICA / AICA / SCA 1.62 0.030 1.05 - 2.50  1.43 0.077 0.96 - 2.14  1.47 0.063 0.98 - 2.19 
PCA  1.93 0.091 0.90 - 4.12  1.84 0.097 0.90 - 3.76  1.81 0.103 0.89 - 3.71 
< 7 mm   1.23 0.104 0.96 - 1.57  1.16 0.223 0.92 - 1.46  1.22 0.119 0.96 - 1.54 
> 7 mm   1.54 <0.001 1.23 - 1.93  1.45 <0.001 1.18 - 1.79  1.47 0.001 1.18 - 1.83 
  
 
Odds ratio for new focal neurological deficit [ND] 
 
Variable  MV OR p-values CI (95 %)  UV OR p-values CI (95 %)  IMP OR p-values CI (95 %) 
 
Age  1.12 0.016 1.02 - 1.24  1.10 0.033 1.01 - 1.19  1.11 0.024 1.02 - 1.20 
Sex  0.90 0.453 0.69 - 1.18  0.88 0.279 0.69 - 1.11  0.96 0.687 0.76 - 1.22 
Pre-SAH mRankin  
Scale 1-2  0.99 0.960 0.65 - 1.50  1.07 0.734 0.72 - 1.58  1.04 0.681 0.75 - 1.46 
Pre-SAH mRankin 
Scale 3-5  1.64 0.336 0.60 - 4.49  2.23 0.098 0.86 - 5.75  1.49 0.399 0.57 - 3.88 
ICA  1.45 0.054 0.99 - 2.12  1.44 0.040 1.02 - 2.03  1.37 0.073 0.98 - 1.92 
MCA  2.17 <0.001 1.56 - 3.03  2.11 <0.001 1.56 - 2.86  2.02 <0.001 1.49 - 2.73 
ACA  1.14 0.627 0.67 - 1.97  1.09 0.720 0.67 - 1.79  1.07 0.771 0.66 - 1.74 
PComm  1.09 0.741 0.65 - 1.85  1.21 0.430 0.75 - 1.96  1.11 0.676 0.68 - 1.82 
VA  1.62 0.307 0.64 - 1.06  1.65 0.214 0.75 - 3.62  1.32 0.514 0.56 - 3.12 
BA  1.46 0.172 0.85 - 2.52  1.48 0.127 0.89 - 2.46  1.47 0.118 0.91 - 2.39 
PICA / AICA / SCA 1.44 0.230 0.79 - 2.61  1.40 0.228 0.81 - 2.43  1.45 0.185 0.85 - 2.49 
PCA  2.53 0.049 1.00 - 6.40  2.13 0.098 0.87 - 5.19  2.25 0.072 0.92 - 5.49 
< 7 mm   1.10 0.584 0.79 - 1.53  1.06 0.729 0.78 - 1.44  1.08 0.642 0.80 - 1.46 
> 7 mm   1.34 0.055 0.99 - 1.79  1.34 0.033 1.03 - 1.76  1.38 0.033 1.05 - 1.82 
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Odds ratio for new cranial nerve palsy [CNP] 
 
Variable  MV OR p-values CI (95 %)  UV OR p-values CI (95 %)  IMP OR p-values CI (95 %) 
 
Age  1.03 0.640 0.92 - 1.14  1.06 0.252 0.96 - 1.16  1.06 0.229 0.97 - 1.16 
Sex  0.89 0.433 0.65 - 1.20  0.86 0.249 0.66 - 1.11  0.93 0.566 0.72 - 1.20 
Pre-SAH mRankin  
Scale 1-2  1.29 0.245 0.84 - 1.99  1.21 0.364 0.80 - 1.83  1.23 0.322 0.83 - 1.83 
Pre-SAH mRankin 
Scale 3-5  0.54 0.421 0.12 - 2.43  0.84 0.786 0.24 - 2.94  0.86 0.510 0.23 - 3.20 
ICA  1.62 0.026 1.06 - 2.47  1.73 0.005 1.18 - 2.52  1.56 0.019 1.08 - 2.26 
MCA  1.92 0.001 1.31 - 2.81  2.08 <0.001 1.48 - 2.92  1.84 0.001 1.30 - 2.58 
ACA  1.14 0.693 0.60 - 2.14  1.13 0.662 0.65 - 1.97  1.12 0.693 0.65 - 1.93 
PComm  1.68 0.066 0.97 - 2.92  1.75 0.029 1.06 - 2.90  1.49 0.129 0.89 - 2.48 
VA  1.58 0.385 0.56 - 4.43  2.13 0.069 0.94 - 4.81  1.71 0.180 0.78 - 3.74 
BA  1.80 0.051 1.00 - 3.25  1.78 0.040 1.03 - 3.01  1.74 0.039 1.03 - 2.95 
PICA / AICA / SCA 1.30 0.472 0.64 - 2.64  1.48 0.219 0.79 - 2.75  1.42 0.272 0.77 - 2.62 
PCA  1.04 0.955 0.29 - 3.67  1.29 0.658 0.42 - 3.92  1.18 0.769 0.37 - 3.75 
< 7 mm   1.19 0.394 0.80 - 1.77  1.18 0.363 0.82 - 1.70  1.22 0.315 0.85 - 1.76 
> 7 mm   1.76 0.001 1.20 - 2.48  1.77 <0.001 1.30 - 2.42  1.64 0.003 1.19 - 2.25 
 
 
 
Odds ratio for being sedated at admission 
 
Variable  MV OR p-values CI (95 %)  UV OR p-values CI (95 %)  IMP OR p-values CI (95 %) 
 
Age  1.07 0.219 0.96- 1.19  1.14 0.009 1.03 - 1.25  1.12 0.009    1.03 - 1.22 
Sex  1.04 0.825 0.76 - 1.40  1.03 0.855 0.79 - 1.33  0.96  0.585    0.75 - 1.22 
Pre-SAH mRankin  
Scale 1-2  1.51 0.157 0.86 - 2.65  1.54 0.114 0.90 - 2.63  1.40 0.305    0.70 - 2.81 
Pre-SAH mRankin 
Scale 3-5  1.46 0.570 0.40 - 5.41  2.42 0.132 0.78 - 7.62  1.03  0.533    0.62 - 1.69 
ICA  1.24 0.337 0.80 - 1.90  1.23 0.293 0.84 - 1.81  1.09  0.530    0.76 - 1.57 
MCA  0.90 0.570 0.61 - 1.32  1.02 0.932 0.72 - 1.43  1.12 0.319    0.79 - 1.58 
ACA  0.96 0.900 0.53 - 1.75  0.81 0.441 0.47 - 1.39  0.99 0.681    0.60 - 1.66 
PComm  0.70 0.223 0.39 - 1.24  0.71 0.205 0.42 - 1.20  0.60 0.077    0.35 - 1.04 
BA  1.65 0.115 0.88 - 3.09  1.56 0.120 0.89 - 2.73  1.54  0.137    0.90 - 2.61 
VA  3.17 0.020 1.20 - 8.39  3.40 0.003 1.52 - 7.61  3.21  0.002    1.53 - 6.74 
PICA / AICA / SCA 1.14 0.709 0.58 - 2.25  0.98 0.936 0.52 - 1.82  1.05  0.691    0.59 - 1.84 
PCA  1.90 0.260 0.62 - 5.81  1.68 0.341 0.58 - 4.89  1.77 0.230    0.68 - 4.60 
< 7 mm   1.05 0.794 0.72 - 1.54  1.04 0.815 0.74 - 1.47  1.19  0.310    0.87 - 1.62 
> 7 mm   1.45 0.032 1.03 - 2.03  1.38 0.037 1.02 - 1.88  1.49 0.038    1.08 - 2.06 
 
 
 
Odds ratio for being intubated at admission 
 
Variable  MV OR p-values CI (95 %)  UV OR p-values CI (95 %)  IMP OR p-values CI (95 %) 
 
Age  1.10 0.080 0.10 - 1.23  1.15 0.003 1.05 - 1.27  1.11 0.013 1.03 - 1.21 
Sex  1.06 0.720 0.78 - 1.43  1.00 0.995 0.77 - 1.30  0.94 0.623 0.75 - 1.19 
Pre-SAH mRankin  
Scale 1-2  1.50 0.159 0.85 - 2.62  1.56 0.101 0.92 - 2.65  1.39 0.149 0.95 - 2.04 
Pre-SAH mRankin 
Scale 3-5  1.92 0.317 0.54 - 6.90  3.19 0.051 1.00 - 10.2  1.32 0.393 0.22 - 7.79 
ICA  1.23 0.340 0.80 - 1.90  1.22 0.317 0.83 - 1.79  1.12 0.507 0.81 - 1.55 
MCA  0.95 0.771 0.64 - 1.39  1.03 0.844 0.74 - 1.45  1.16 0.402 0.85 - 1.58 
ACA  0.93 0.823 0.52 - 1.70  0.78 0.369 0.46 - 1.34  1.02 0.828 0.64 - 1.63 
PComm  0.91 0.743 0.53 - 1.57  0.90 0.686 0.55 - 1.48  0.76 0.312 0.45 - 1.27 
BA  1.88 0.046 1.01 - 3.50  1.84 0.030 1.06 - 3.19  1.58 0.100 0.94 - 2.64 
VA  3.04 0.025 1.15 - 8.02  3.27 0.004 1.46 - 7.32  2.85 0.003 1.43 - 5.67 
PICA / AICA / SCA 1.10 0.777 0.56 - 2.19  1.02 0.944 0.55 - 1.89  1.08 0.674 0.63 - 1.85 
PCA  1.86 0.280 0.64 - 5.70  1.60 0.385 0.55 - 4.66  1.79 0.202 0.72 - 4.48 
< 7 mm   1.13 0.518 0.78 - 1.65  1.12 0.511 0.80 - 1.58  1.28 0.103 0.96 - 1.72 
> 7 mm   1.51 0.017 1.08 - 2.11  1.45 0.015 1.08 - 1.96  1.59 0.002 1.22 - 2.09 
 
  
  
Odds ratio for ͞high͟ Fisher score  
 
Variable  MV OR p-values CI (95 %)  UV OR p-values CI (95 %)  IMP OR p-values CI (95 %) 
 
Age  1.09 0.044 1.00 - 1.17  1.09 0.018 1.01 - 1.17  1.08 0.042 1.00 - 1.16 
Sex  0.98 0.836 0.78 - 1.22  0.94 0.503 0.77 - 1.14  0.94 0.577 0.77 - 1.16 
Pre-SAH mRankin  
Scale 1-2  1.12 0.534 0.79 - 1.58  1.18 0.327 0.85 - 1.63  1.14 0.434 0.83 - 1.55 
Pre-SAH mRankin 
Scale 3-5  1.54 0.411 0.55 - 4.32  1.55 0.328 0.65 - 3.71  1.10 0.641 0.44 - 2.72 
ICA  0.85 0.296 0.62 - 1.16  0.85 0.278 0.64 - 1.14  0.82 0.183 0.61 - 1.01 
MCA  1.39 0.025 1.04 - 1.85  1.25 0.091 0.97 - 1.62  1.22 0.139 0.94 - 1.60 
ACA  1.14 0.555 0.74 - 1.76  0.98 0.913 0.66 - 1.45  1.02 0.931 0.68 - 1.52 
PComm  1.08 0.708 0.71 - 1.65  1.04 0.854 0.70 - 1.53  0.96 0.859 0.65 - 1.44 
VA  1.69 0.184 0.78 - 3.69  1.84 0.068 0.96 - 3.53  1.79 0.083 0.93 - 3.44 
BA  1.09 0.725 0.69 - 1.71  1.01 0.947 0.67 - 1.54  0.97 0.889 0.64 - 1.48 
PICA / AICA / SCA 1.52 0.093 0.93 - 2.49  1.52 0.073 0.96 - 2.39  1.53 0.070 0.97 - 2.42 
PCA  2.22 0.058 0.97 - 5.07  2.17 0.054 0.99 - 4.78  2.17 0.055 0.98 - 4.78 
< 7 mm   0.81 0.140 0.62 - 1.07  0.82 0.128 0.63 - 1.06  0.85 0.238 0.66 - 1.10 
> 7 mm   1.15 0.258 0.90 - 1.48  1.16 0.221 0.92 - 1.46  1.18 0.170 0.94 - 1.48 
 
 
Odds ratio for presence of a thick clot  
 
Variable  MV OR p-values CI (95 %)  UV OR p-values CI (95 %)  IMP OR p-values CI (95 %) 
 
Age  1.21     0.002    1.07 - 1.36  1.16 0.009   1.04 - 1.29  1.18     0.003    1.06 - 1.32 
Sex  1.18     0.336    0.84 - 1.66  1.15  0.379   0.84 - 1.56  1.18     0.317    0.86 - 1.62 
Pre-SAH mRankin  
Scale 1-2  0.99 0.960 0.65 - 1.50  0.93 0.759 0.59 - 1.48  0.90 0.570 0.54 - 1.52 
Pre-SAH mRankin 
Scale 3-5  1.64 0.340 0.60 - 4.49  1.20 0.810 0.27 - 5.26  0.86 0.616 0.17 - 4.21 
ICA  0.82     0.362    0.53 - 1.26  0.78  0.224   0.52 - 1.17  0.76     0.204    0.56 - 1.16 
MCA  1.42     0.117    0.96 - 2.21  1.25 0.278   0.84 - 1.87  1.24    0.318   0.82 - 1.87 
ACA  1.14     0.689    0.60 - 2.17  1.02 0.953   0.56 - 1.85  1.07     0.824    0.59 - 1.96 
PComm  1.43     0.314    0.76 - 2.85  1.16 0.634   0.63 - 2.14  1.09     0.780    0.58 - 2.05 
BA  1.14     0.714    0.57 - 2.28  1.10 0.767   0.58 - 2.12  1.06     0.855    0.55 - 2.07  
VA  1.96     0.369    0.45 - 8.54  2.56 0.202   0.60 - 10.9  2.50     0.215    0.59 - 10.7 
PICA / AICA / SCA 1.69     0.216    0.74 - 3.86  1.25 0.552   0.60 - 2.61  1.32     0.463    0.63 - 2.77 
PCA  3.89     0.189    0.51 - 29.6  3.67 0.206   0.49 - 27.5  3.97     0.182    0.53 - 30.0 
< 7 mm   0.97     0.898    0.66 - 1.45  0.96 0.847   0.66 - 1.41  0.98     0.900    0.67 - 1.42  
> 7 mm   1.27     0.205    0.88 - 1.84  1.22  0.271   0.86 - 1.74  1.24     0.238    0.87 - 1.76 
 
 
Suppl. Data Table 1: Correlation tables.   
Correlation tables of multivariate analysis [MV], univariate analysis [UV] and analysis of imputed data of 
missing values [IMP]. Data was dichotomized into „high” GCS score (GCS ≥ 13) versus „low” GCS score (GCS 
≤ 12), “high” WFNS grade (WFNS grade IV-V) versus “low” WFNS grade WFNS score (I-III), and “high” 
Fisher grade (III-IV) versus “low” Fisher grade (Fisher grade I-II). 
 
  
 
 
Suppl. Data Figure 1: Forest plots.  
A) Mixed effects logistic regression model for „good GCS grade” at admission defined as GCS ≥ 13 compared 
to „bad GCS grade” defined as a GCS ≤ 12. B) Mixed effects logistic regression model for “good WFNS grade” 
at admission defined as WFNS score I-III compared to “bad WFNS grade” defined as WFNS grade IV-V. C) 
Mixed effects logistic regression model for “high Fisher grade” at admission defined as Fisher grade III-IV 
compared to “low Fisher grade” defined as Fisher grade I-II. D) Mixed effects logistic regression model for 
  
finding a thick clot defined as a blood clot >3.5mm in an axial plain on the admission CT compared to not 
finding a thick clot on admission CT. E) Mixed effects logistic regression model for finding a new focal 
neurological deficit on admission exam compared to not finding a new focal neurological deficit. F) Mixed 
effects logistic regression model for finding a new cranial nerve palsy on admission exam compared to not 
finding a new cranial nerve palsy. G) Mixed effects logistic regression model for being intubated at admission 
compared to not being intubated. Remark: The models included the following variables: age (age-groups of 10 
years), sex (reference: female), aneurysm multiplicity (reference: single intracranial aneurysm), Pre-SAH mRS 
(reference: mRS 0), location of the index aneurysm (reference: ACommA), and size of the index aneurysm 
(reference: maximal diameter < 5mm). The corresponding multivariate analysis with imputed data of missing 
values is provided in Additional file 1. Significance is indicated as follows: ns (p > .05), * (p ≤ .05), ** (p ≤ .01), 
*** (p ≤ .001), **** (p ≤ .0001). CI: confidence interval 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Suppl. Data Figure 2: Frequency tables. 
A) Pre-SAH mRS distribution in function of patient age. B) GCS at admission in function of patient age. C) 
WFNS grade in function of patient age. D) Fisher grade at admission in function of patient age. Remark: mRS: 
modified Rankin Scale; GCS: Glasgow Coma Scale; WFNS: Word Federation of Neurosurgeons Score. 
